A Nimble And Flexible Solution To Rescuing An Observational Study

Focused on developing therapies for cancer patients, a European Biotech was looking to improve patient recruitment efforts across more than 145 sites in North America and Europe for an observational retrospective study of therapies for relapsed or refractory diffuse large B cell lymphoma. In 2020, the sponsor engaged Novotech for regulatory and clinical study management for the expansion into Asia Pacific (APAC) – with the addition of new sites in Australia, South Korea, and Taiwan.

Discover how with strong local expertise and a flexible, nimble approach in accommodating the sponsor the team was able to facilitate rapid study start-up of APAC sites and recruitment of 500 patients to expedite the study’s global recruitment milestone and meet the FDA submission deadline.